31 patents
Utility
Treatments of Angioedema
30 Nov 23
The present invention relates to treatments of bradykinin-mediated angioedema.
John Alexander COOPER, Edward Paul FEENER, Andreas MAETZEL, Sally Louise MARSH, Michael David SMITH, Christopher Martyn YEA
Filed: 22 Oct 21
Utility
Enzyme Inhibitors
10 Aug 23
Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
Filed: 27 Mar 23
Utility
Enzyme inhibitors
28 Mar 23
Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Alessandro Mazzacani, Michael John Stocks, Thomas Matthew Baker, Matthew Robert Conroy, Alun John Smith, David Edward Clark
Filed: 8 Oct 21
Utility
Solid forms of a plasma kallikrein inhibitor and salts thereof
21 Feb 23
New solid forms of the plasma kallikrein inhibitor, 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts, are described.
David Malcolm Crowe, Edwin Aret, Kiran Gandhi, Ruben Henricus Carolus Adrianus Titus Lelieveld, Emma Kay Sharp, Richard Simon Todd
Filed: 29 Nov 18
Utility
Treatments of Diabetic Macular Edema and Impaired Visual Acuity
22 Dec 22
Edward Paul FEENER, Michael David SMITH, Christopher Martyn YEA
Filed: 9 Dec 20
Utility
Enzyme Inhibitors
17 Nov 22
Hannah Joy EDWARDS, David Michael EVANS, Alessandro MAZZACANI, Alicja Stela OBARA, David Edward CLARK, Emanuela GANCIA, Rachael PITTAWAY, Joseph William WRIGGLESWORTH
Filed: 13 Feb 20
Utility
Enzyme Inhibitors
22 Sep 22
Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Sally Louise MARSH, Alessandro MAZZACANI, David Philip ROOKER, Michael John STOCKS, Andrew Peter CRIDLAND, Emanuela GANCIA, Julie Nicole HAMBLIN, Paul Stuart HINCHLIFFE, Stefano LEVANTO, Terence Aaron PANCHAL, Iain Robert MILLER
Filed: 21 Aug 19
Utility
Enzyme Inhibitors
22 Sep 22
Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Andrew Peter CRIDLAND, Emanuela GANCIA, Erica Lee GOLDSMITH, Paul Stuart HINCHLIFFE, Karamjit Singh JANDU, Alun John SMITH
Filed: 21 Aug 19
Utility
Enzyme Inhibitors
15 Sep 22
The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.
Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, David Edward CLARK, Paul Stuart HINCHLIFFE, Thomas Matthew BAKER, Colin Peter SAMBROOK SMITH, Alun John SMITH, Joseph William WRIGGLESWORTH, Xuezheng YANG
Filed: 13 Feb 20
Utility
N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors
15 Sep 22
Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
Filed: 20 Oct 21
Utility
Treatments of Angioedema
21 Jul 22
The present invention relates to treatments of angioedema, and specifically bradykinin-mediated angioedema non-hereditary (BK-AEnH).
Edward Paul FEENER, Sally Louise MARSH, Andreas MAETZEL, Michael David SMITH, Christopher Martyn YEA
Filed: 15 Jun 20
Utility
Treatments of Hereditary Angioedema
14 Jul 22
The present invention relates to treatments of hereditary angioedema (HAE).
Edward Paul FEENER, Sally Louise MARSH, Andreas MAETZEL, Michael David SMITH, Christopher Martyn YEA
Filed: 15 Jun 20
Utility
Enzyme Inhibitors
17 Feb 22
Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, Michael John STOCKS, Thomas Matthew BAKER, Matthew Robert CONROY, Alun John SMITH, David Edward CLARK
Filed: 8 Oct 21
Utility
Polymorphs of N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE and Salts Thereof
10 Feb 22
The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
Haydn BEATON, David Malcolm CROWE, Hannah Joy EDWARDS
Filed: 20 Oct 21
Utility
Inhibitors of plasma kallikrein
8 Feb 22
Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
Filed: 22 Jan 19
Utility
Dosage forms comprising a plasma kallikrein inhibitor
1 Feb 22
The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A.
John Herman Collett, Gary Paul Cook, Jamie Joseph Farrar, Michael John Frodsham, Michael Bryan Roe, Richard Simon Todd, Robert Neil Ward
Filed: 28 Nov 18
Utility
Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitors
25 Jan 22
Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards, Nicholas James Griffiths-Haynes
Filed: 1 Jun 17
Utility
Enzyme Inhibitors
6 Jan 22
Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
Filed: 21 Sep 21
Utility
N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
14 Dec 21
Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson
Filed: 28 Feb 20
Utility
Pyrazole derivatives as plasma kallikrein inhibitors
23 Nov 21
Rebecca Louise Davie, Hanna Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
Filed: 31 May 17